Quotient Sciences Integrates Pharmaterials Acquisitions
By

Quotient Sciences, a Nottingham, UK-based contract development and manufacturing organization (CDMO), has completed the integration and rebrand of Pharmaterials, a CDMO based in Reading, UK. Quotient Sciences acquired Pharmaterials in November 2017.

Pharmaterials, now named Quotient Sciences (Reading), will play a role in expanding and strengthening Quotient’s service portfolio from preclinical formulation development through to commercial manufacturingand support the growth of Quotient’s Translational Pharmaceutics platform.

The Reading business is focused on the development of small-molecule drug products for oral and inhaled delivery and supports Quotient’s formulation development and manufacturing services. Pharmaterials’ 48,000-square-foot facility includes an additional 13 GMP manufacturing suites, high-potency containment capabilities and experience across solubilization technologies, including spray drying, hot-melt extrusion, lipidic systems, and micronization.

Source: Quotient Sciences

 

Leave a Reply

Your email address will not be published.